Syntheses and Cytotoxicity of (R)- and (S)-7-Methoxycryptopleurine by Anton-Torrecillas, Cintia et al.
Syntheses and Cytotoxicity of (R)- and (S)-7-Methoxycryptopleurine  
Cintia Anton-Torrecillas,a Irene Bosque,a Jose C. Gonzalez-Gomez,a,* María Isabel 
Lozab and José Breab  
a Departamento de Química Orgánica, Facultad de Ciencias and Instituto de Síntesis 
Orgánica (ISO), Universidad de Alicante, Apdo. 99, 03080 Alicante, Spain.  
b Grupo de Investigación Biofarma. USEF screening platform. Centro de Investigación 
en Medicina Molecular y Enfermedades Crónicas (CIMUS). Universidad de Santiago 
de Compostela. Avda de Barcelona s/n. Santiago de Compostela, Spain. 
josecarlos.gonzalez@ua.es 
 
HN
S
O
t-Bu
R1
OMe
MeO
MeO
OMe
N
Boc
N
OMe
MeO
MeO
OMe
H
H
(R)-7-methoxycryptopleurine
hydroformylation
Ar
N
S
t-Bu
H
O
Ar
RCM
two steps
two steps
32 % yield
96:4 er
46 % yield
>99:1 er
two steps
two steps
HL-60:                38 nM
NCI-H460:        130 nM
MCF-7:               27 nM
NCI-ADR-RES: 110 nM
IC50
 
ABSTRACT: Two efficient protocols are described for the transformation of a key 
chiral homoallyllic sulfinamine intermediate in four steps into enantioenriched 7-
methoxycryptopleurine. While one of the protocols relied on a rhodium catalyzed linear 
hydroformylation process, the alternative approach was based on a ring-closing 
metathesis from the corresponding N-allyl-sulfinamine. The cytotoxic evaluation of 
both enantiomers of the target compound demonstrated that the (R)-compound is much 
more potent than its antipode against the four cancer cell lines examined. 
 
 
Phenanthroizidine alkaloids exhibit a polyoxygenated phenanthrene ring fused to an 
indolizidine or to a quinolizidine system (Figure 1).1  Importantly, while the 
indolizidine moiety prefers a cis-fused conformation,2 trans-fused quinolizidines are 
preferred.3 The stereochemistry of the pyramidal nitrogen at the ring junction may 
accounts for some important differences between the bioactivities of these subfamilies 
of alkaloids.4  
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Figure 1. Representative natural phenanthroizidine alkaloids. 
 
Cryptopleurine5 and Cryptopleuridine6 were the only two natural 
phenathroquinolizidines known until 2002. Despite their lower natural occurrence 
compared to the indolizidine subfamily, phenanthroquinolizidines also exhibit very 
interesting bioactivities. This issue can be exemplified by Boehmeriasin A, which was 
identified in 20037 and exhibited IC50 in the low nanomolar range against twelve cancer 
cell lines.8 Other structure-activity relationships (SAR) studies have also revealed that 
phenanthroquinolizidines are more potent anti-tumor agents than 
phenanthroindolizidine alkaloids.9 Encouraged by the discovery of natural 
phenanthroquinolizidines with important biological properties, some elegant 
asymmetric syntheses have been recently reported for these compounds. 10,11  
It is reported that racemic 7-methoxycryptopleurine12 displays potent anti-inflamatory 
activity,13 as well as remarkable cytotoxicity at submicromolar concentrations against 
different human cancer cell lines.3a,14 In addition, the group of Wang has found that both 
enantiomers of the title compound show significant antiviral activity (in vitro and in 
vivo) against tobacco mosaic virus (TMV), being the R-enantiomer the most active 
one.15 Moreover, the same group has recently reported that different salts of the title 
compound, or derivatives where the methyl groups were removed, gave excellent anti 
TMV activity. 16 To our best knowledge, the only enantioselective synthesis reported 
for this promising bioactive compound takes place with partial racemization over a 
Parham-type cycloacylation. 17 
Prompted by the unique biological activities of 7-methoxycryptopleurine and the lack of 
efficient protocols for its preparation with high enantiomeric purity, we report herein 
two alternative protocols for the synthesis of enantioenriched (R)- and (S)-7-
methoxycryptopleurine. Both synthetic strategies relied on a late Pictet-Spengler 
formation of ring D18 and the formation of ring E was examined using either 
hydroformylation or ring-closing metathesis (RCM)19 as the key steps, from the same 
chiral homoallylic sulfinamine intermediate 20 (Scheme 1). Since we have previously 
shown that these chiral intermediates can be efficiently transformed into 
phenanthroindolizidines, 21 this work illustrates the versatility of these building blocks 
in the synthesis of both subfamilies of phenanthroizidine alkaloids. 22 
Scheme 1. Divergent synthesis of two subfamilies of phenanthroizidine alkaloids.  
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 Our first strategy to build ring E of (R)-7-methoxycryptopleurine is based on a linear 
hydroformylation of the corresponding homoallylic amine intermediate. This approach 
has been widely used for a range of aminoalkenes in order to provide terminal 
aldehydes, which upon cyclization give enamine intermediates that can be transformed 
into different aza-heterocycles.23 In this regard, we were particularly attracted by a 
rhodium catalyzed procedure where the syngas (CO/H2) is conveniently substituted by 
formaldehyde, with excellent linear selectivity.24 To minimize functional group 
manipulations and reduce the number of steps, we first tried the direct hydroformylation 
of sulfinamine 1, which can be prepared in six steps from commercially available 
starting materials21 (Scheme 2). However, compound 1 proved to be unreactive under 
different conditions reported in the literature for the rhodium(I) catalyzed 
hydroformylation with formalin (37% aq. formaldehyde) or paraformaldehyde. We thus 
prepared the N-Boc protected homoallylic amine 2, which was submitted to rhodium(I) 
catalyzed hydroformylation with formalin, using two different phosphane ligands 
(BIBHEP and Ni-Xantphos). Under these conditions, the formation of the 
corresponding terminal aldehyde was followed by in-situ cyclization to furnish the 
protected enamine 3 in moderate yield (Scheme 2). Subsequent hydrogenation of the 
enamine moiety followed by acidic cleavage of the Boc group took place efficiently to 
obtain piperidine 4. Finally, the Pictet-Spengler cyclomethylenation of this precursor 
was accomplished under standard conditions (formalin, HCl, EtOH, 90 ºC) to obtain the 
target (R)-7-methoxycryptopleurine in good yield. The spectroscopic data obtained for 
compound 5 perfectly match with data previously reported for racemic 7-
methoxycryptopleurine 3a and the chiral HPLC analysis of this compound shows that 
racemization did not take place over the synthetic sequence (96:4 er, see SI). It is worth 
noting that the absolute configuration of compound 5 was confirmed to be 14a-R by 
comparison of the specific rotation value obtained for our synthetic sample {[α]D20 −81 
(c 1.0, CHCl3)} with the one reported in the literature17 {[α]D20 −74.8 (c 0.5, CHCl3)}. 
Scheme 2: Synthesis of (R)-7-Methoxycryptopleurine using Hydroformylation 
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Despite the good results obtained in the synthesis of compound (R)-5 [32% yield over 
four purification steps from compound 1 to obtain (R)-5 in 96:4 er], we were 
particularly interested in keeping the sulfinyl as protecting group throughout the 
synthetic sequence. With this strategy we anticipated a concomitant nitrogen 
deprotection and Pictet Spengler annulation in the final step. More importantly, we 
expected that keeping the chiral auxiliary until the last step would offer more 
opportunities to improve the enantiomeric purity of compound 5 by separation of 
diastereomeric intermediates. To carry forward this approach (Scheme 3) we first 
performed the N-allylation of compound 6,25 followed by ring-closing metathesis 
(RCM). At the outset it was not clear if the sulfinyl group would compete with the 
alkene moiety by the ruthenium carbene complex, preventing the desired cyclization.26 
Remarkably, after only one hour at room temperature, the use of commercially available 
second-generation Grubbs catalyst allowed the RCM reaction to proceed with almost 
quantitative yield. Catalytic hydrogenation of intermediate 8a was accomplished by 
using Adams`s catalyst to give compound 9a,27 followed by acidic removal of the 
sulfinyl group and Pictet Spengler annulation. Phenanthroquinolizidine (S)-10 was 
obtained in 68% yield over four purification steps from compound 6. The same 
synthetic sequence was applied to obtain (R)-10 from ent-6 with similar efficiency in 
terms of isolated yields, and neither racemization nor significant enantioenrichment was 
observed by chiral HPLC analysis of the products (see SI). Having developed this 
protocol, we thus carried out the synthesis of target compound (S)-5 from compound 
ent-1.21 Importantly, this synthetic protocol allowed the preparation of (S)-7-
methoxycryptopleurine as a single isomer (>99:1 er by HPLC analysis), in 46% yield 
over four purification steps. The enantioenrichment of the target compound was simply 
achieved after conventional flash chromatography purifications of diastereomeric 8b 
and 9b intermediates, according to chiral HPLC analysis (see SI). 
Scheme 3. Synthesis of Phenanthroquinolizidines using RCM 
HN
S
R
R
R
R
t-Bu
N
R
R
R
R
6: R= H, 95:5 dr
ent-1: R= OMe, 95:5 dr
S
N
R
R
R
R
N
R
R
R
R
S
N
R
R
R
R
7a: 85% 
7b: 73%
8a: 95% 
8b: 93%, 97:3 dr
9a: 93%, 95:5 dr 
9b: 84%, >99:1 dr after chromatography
(S)-10: 91%, 95:5 er 
(S)-5: 81%, >99:1 er
Br
KHMDS
THF, 0 ºC
 G-II cat.
0.04 M CH2Cl2
25 ºC, 1 h
H2, PtO2
 CH2Cl2/ EtOAc
ent-6                                                                                          (R)-10 (96:4 er)
same sequence
O
t-Bu O S
t-Bu O
Ot-Bu
1) Deprotection
2) Pictet Spengler
 
 
The cytotoxic activities of synthesized (R)-and (S)-7-methoxycryptopleurine were tested 
against four human cancer cell lines, using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltretrazolium bromide) method and CDDP [cis-diaminedichloroplatinum (II)] as 
positive control. The IC50 values were determined from the corresponding 
inhibition/concentration curves (see SI) and the results are shown in Table 1. In all the 
cell lines evaluated the compound with the (R)-configuration (as natural analogues) was 
much more potent (IC50 from 0.027 to 0.13 µM) than its (S)-enantiomer (IC50 from 0.97 
to 76 µM), confirming the importance of this configuration in their cytotoxicity. The 
cytotoxicity obtained for compound (R)-5 against human lung cancer cell lines (NCI-
H460) was similar to the one previously reported3a for a racemic sample. However, for 
human breast cancer cell lines (MCF-7), compound (R)-5 showed a significant higher 
potency than it is reported for a racemic sample. A profound cytotoxicity was also 
exhibited by compound (R)-5 against human leukemia cells (HL-60); and most 
significantly against drug resistant human ovarian adenocarcinoma (NCI-ADR-RES), 
where paclitaxel -a potent anticancer agent-11 is inactive. 
Table 1. Cytotoxicity Evaluation of (R)-and (S)-7-Methoxycryptopleurine  
Compounds 
IC50 (µM)a 
HL-60b NCI-H460c MCF-7d NCI-ADR-RESe 
CDDP 12 ± 1 7.3 ± 0.3 12 ± 1 11 ± 1 
(±)-5 − 0.11f 0.10f − 
(R)-5 HCl 0.038 ± 0.001 0.13 ± 0.06 0.027 ± 0.001 0.11 ± 0.02 
(S)-5 HCl 0.97 ± 0.04 76g ± 11 1.2 ± 0.1 11g ± 4 
aAverage of three assays each. bHL-60 = human promyelocytic leukemia. cNCI-H460 = human 
lung carcinoma. dMCF-7 = human breast carcinoma. eNCI-ADR-RES= drug-resistant human 
ovarian adenocarcinoma. fTaken from reference 3a. gExtrapolated values from an incomplete 
concentration-response curve (see SI). 
 
In conclusion, we have developed two alternative procedures that allow the 
enantioselective preparation of 7-methoxycryptopleurine (5) in four purification steps 
from the same chiral homoallyllic sulfinamine. The synthetic approach that make use of 
linear hydroformylation for the construction of ring E afforded the target compound in 
good overall yield (32%) and enantiomeric purity (96:4 er). However, better results 
were obtained using the ring-closing metathesis of the N-allyl-sulfinamine intermediate 
(46% overall yield in >99:1 er). The cytotoxicity of each enantiomer of compound 5 
was evaluated against four cancer cell lines, including a drug-resistant cancer cell line, 
obtaining more prominent activities for the (R)-antipode (IC50 up to 27 nM). To the best 
of our knowledge, the two procedures developed herein allow the preparation of the 
target compound with the highest enantiomeric purity reported to date. The 
cytotoxicities obtained for compound (R)-5 clearly support this candidate as a promising 
anticancer agent. 
 
EXPERIMENTAL SECTION 
General Remarks. TLC was performed on silica gel 60 F254, using aluminum plates 
and visualized by exposure to ultraviolet light or with phosphomolybdic acid (PMA) 
stain. Flash chromatography was carried out on handpacked columns of silica gel 60 
(230 − 400 mesh). Melting points are uncorrected. Optical rotations were measured 
using a polarimeter with a thermally jacketted 5 cm cell at approximately 20 ºC and 
concentrations (c) are given in g/100 mL. Infrared analysis was performed with a 
spectrophotometer equipped with an ATR component; wavenumbers are given in cm-1. 
HRMS analyses were carried out using the Electron Impact (EI) mode at 70 eV or by Q-
TOF using Electro Spray Ionization (ESI) mode. HPLC analyses were performed using 
an achiral Tracer Excel 120 column for the determination of diastereomeric ratios and a 
Chiralcel AD-H column for enantiomeric ratios. 1H NMR spectra were recorded at 300 
or 400 MHz for 1H NMR and 75 or 100 MHz for 13C NMR, using CDCl3 as the solvent 
and TMS as an internal Standard (0.00 ppm). The data is being reported as (s = singlet, 
d = doublet, t = triplet, m = multiplet or unresolved, br s = broad signal, coupling 
constant(s) in Hz, integration). 13C NMR spectra were recorded with 1H-decoupling at 
100 MHz and referenced to CDCl3 at 77.16 ppm. DEPT-135 experiments were 
performed to assign CH, CH2 and CH3. 
 
(R)-tert-Butyl-1-(2,3,6,7-tetramethoxyphenanthren-9-yl)pent-4-en-2-ylcarbamate 
(2). To a solution of compound 121 (596 mg, 1.23 mmol, 95:5 dr) in MeOH (15 mL) 
was added a solution of 4M HCl in dioxane (1.2 mL, 5.00 mmol) at 0 ºC. The cooling 
bath was removed and the reaction mixture was stirred 1.5 h at 25 ºC, before being 
concentrated to dryness. The resulting free amine was dissolved in CH2Cl2 (12 mL) and 
after cooled down the solution to 0 ºC, a solution of 2 M NaOH (12 mL) and Boc2O 
(304 mg, 1.40 mmol) were sequentially added. The mixture was stirred under argon 
atmosphere at 25ºC during 2.5 h. The mixture was extracted with CH2Cl2 (5 x 10 mL) 
and the collected organic layers were washed with brine (5 mL), dried over MgSO4 and 
concentrated to dryness. The crude product was purified by flash chromatography 
(hexane/EtOAc from 7:3 to 1:1) to obtain the desired product as a white amorphous 
solid (458 mg, 78%): [α]D20 −10 (c 0.4, CHCl3); Rf 0.26 (7:3 hexane/EtOAc); IR ν 
3363, 3355, 3002, 2928, 2830, 1687, 1253, 1148, 1038, 835 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.93 (s, 1H), 7.83 (s, 1H), 7.78 (s, 1H), 7.39 (s, 1H), 7.16 (s, 1H), 5.91 – 5.76 
(m, 1H), 5.15 –  5.11 (m, 2H), 4.62 (br s, 1H), 4.16 (s, 3H), 4.13 (s, 3H), 4.12 (s, 3H), 
4.03 (s, 3H), 3.80 – 3.73 (m, 1H), 3.68 – 3.54 (m, 1H), 2.96 – 2.84 (m, 1H), 2.41 – 2.29 
(m, 1H), 2.25 – 2.11 (m, 1H), 1.44 (s, 9H) ppm; 13C NMR (101 MHz, CDCl3) δ 155.6 
(C), 149.08 (C), 149.05 (C), 148.9 (C), 134.6 (CH), 130.6 (C), 126.2 (C), 125.9 (C), 
125.7 (CH), 124.9 (C), 124.0 (C), 118.4 (CH2), 108.0 (CH), 105.9 (CH), 103.3 (CH), 
102.9 (CH), 56.5 (CH3), 56.2 (CH3), 56.1 (CH3), 56.0 (CH3), 50.2 (CH), 39.8 (CH2), 
37.7 (CH2), 28.5 (C) ppm; HRMS (ESI-TOF) m/z calcd for C28H35NO6Na 504.2362, 
found 504.2366. 
(R)-tert-Butyl-2-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)-3,4-
dihydropyridine-1-(2H)-carboxylate (3). To a pressure tube were sequentially added 
[RhCl(cod)]2 (3.10 mg, 0.0062 mmol), BIPHEP (6.63 mg, 0.0126 mmol), Ni-Xantphos 
(2.9 mg, 0.0126 mmol) and toluene (3.7 mL). The system was then evacuated and filled 
with argon before compound 2 (300 mg, 0.621 mmol) and aqueous formalin (37%, 0.2 
mL, 8.40 mmol) were added. The reaction mixture was deoxygenated via three cycles of 
freeze-pump and thaw under argon atmosphere and heated to 90 ºC. The mixture was 
stirred for 40 h at the same temperature and then left to reach room temperature, before 
being concentrated and purified by flash chromatography (hexane/EtOAc 7:3) to obtain 
the desired product as a white amorphous solid (188 mg, 61 %): [α]D20 −51 (c 1.0, 
CHCl3); Rf 0.33 (7:3 hexane/EtOAc); IR ν 2998, 2965, 2928, 2837, 1689, 1651, 1251, 
752 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.83 (s, 1H), 7.79 (s, 1H), 7.38 (s, 
1H), 7.17 (s, 1H), 6.83 (d, J = 8.4 Hz, 1H), 4.94 – 4.85 (m, 1H), 4.79 – 4.66 (m, 1H), 
4.23 (s, 3H), 4.13 (s, 3H), 4.12 (s, 3H), 4.03 (s, 3H), 3.45 (dd, J = 13.7, 2.9 Hz, 1H), 
3.09 – 2.95 (m, 1H), 2.52 – 2.38 (m, 1H), 2.08 – 1.96 (m, 1H), 1.79 – 1.69 (m, 1H), 1.51 
(s, 9H) ppm; 13C NMR (101 MHz, CDCl3) δ 152.2 (C), 149.2 (C), 149.05 (C), 149.01 
(C), 148.8 (C), 130.8 (C), 126.2 (C), 126.1 (C), 125.7 (CH), 124.9 (C), 124.7(CH), 
124.1(C), 108.0 (CH), 106.3 (CH), 104.0 (CH), 103.1 (CH), 103.0 (CH), 80.7(C), 56.7 
(CH3), 56.2 (CH3), 56.1 (CH3), 56.01 (CH3), 49.6 (CH), 35.1 (CH2), 28.5 (CH3), 21.9 
(CH2), 17.6 (CH2) ppm; HRMS (ESI-TOF) m/z calcd for C29H35NO6Na 516.2362, 
found 516.2343. 
(R)-2-((2,3,6,7-Tetramethoxyphenanthren-9-yl)methyl)piperidine (4). A dry flask 
was charged with compound 3 (168 mg, 0.34 mmol), Pd(OH)2 (20 % Pd on carbon 
powder with ca 60 % moisture, 98 mg, 0.09 mmol) and methanol (10 mL). A ballon of 
hydrogen gas was fitted to the equipment, and the flask was opened to vacuum for a few 
seconds, and then switched to the hydrogen ballon; this manipulation was repeated three 
times. The reaction mixture was allowed to stir at room temperature for 6 h. It was then 
filtered throught Celite, washing with EtOAc (3 x 15 mL), and the organic solution was 
concentrated to dryness under reduced pressure. To the obtained residue were added 
methanol (3.0 mL), trifluoroacetic acid (3.0 mL, 28.00 mmol) and CH2Cl2 (3 mL) and 
the reaction mixture was stirred under argon at room temperature for 24 h. After the 
mixture was concentrated to dryness, a solution 2 M of NaOH (5 mL, 10 mmol) and 
CH2Cl2 (10 mL) were added to the same flask. The aqueous phase was extracted with 
CH2Cl2 (3 x 10 mL) and washed with brine (5 mL), dried over Na2SO4, and 
concentrated. The crude product was obtained as a brown amorphous solid (109 mg, 89 
%): [α]D
20 −4.8 (c 0.5, CHCl3); Rf 0.27 (95:5, CH2Cl2/MeOH); 1H NMR (300 MHz, 
CDCl3) δ 7.83 (s, 1H), 7.76 (s, 1H), 7.46 (s, 1H), 7.42 (s, 1H), 7.16 (s, 1H), 4.12 (s, 
3H), 4.11 (s, 3H), 4.06 (s, 3H), 4.02 (s, 3H), 3.24 (dd, J = 13.4, 4.6 Hz, 1H), 3.11 – 2.87 
(m, 3H), 2.51 (td, J = 11.5, 3.0 Hz, 1H), 1.88 – 1.72 (m, 2H), 1.55 – 1.26 (m, 4H) ppm; 
13C NMR (75 MHz, CDCl3) δ 149.1 (C), 149.0 (2xC), 148.7 (C), 130.5 (C), 126.3 (C), 
125.6 (CH), 125.5 (C), 125.2 (C), 123.9 (C), 108.1 (CH), 105.2 (CH), 103.5 (CH), 
102.9 (CH), 56.7 (CH3), 56.3 (CH3), 56.2 (CH3), 56.0 (CH3), 47.2 (CH), 41.6 (CH2), 
33.4 (CH2), 26.1 (CH2), 25.0 (CH2) ppm; HRMS (ESI-TOF) m/z calcd for C24H30NO4 
396.2175, found 396.2172. 
(R)-7-Methoxycryptopleurine ((R)-5). To a solution of compound 4 (100 mg, 0.25 
mmol) in EtOH (6 mL) was added 37% aqueous formaldehyde (1.25 mL) and 
concentrated HCl (12 M, 0.18 mL). The mixture was put under argon atmosphere in the 
dark and heated to 90 ºC with stirring for 48 h. After cooled to room temperature, the 
mixture was concentrated and distributed between 2 M solution of NaOH (10 mL) and 
CH2Cl2 (15 mL). The aqueous phase was extracted with CH2Cl2 (3 x 15 mL) and the 
collected organic layers were washed with brine (5 mL), dried over Na2SO4, and 
concentrated in vacuum. The crude product was purified by flash chromatography 
(72:25:2:1, hexane/CH2Cl2/EtOH/TEA), to obtain the desired product as a yellow solid 
(185 mg, 76%): mp 236-240 ºC (descomp.); {lit.3a mp 245-247 ºC (descomp.)}; [α]D20 
−81 (c 1.0, CHCl3) {lit.17 [α]D20 −74.8 (c 0.5, CHCl3)}; Rf 0.15 (72:25:2:1, 
hexane/CH2Cl2/EtOH/TEA); 96:4 er according to chiral HPLC analysis [tR (minor) 
14.98 min, tR (major) 15.99 min, see SI for details]; IR ν 2959, 2911, 2831, 1614, 1511, 
1426, 1244, 1153, 838, 770 cm-1.  1H NMR (300 MHz, CDCl3) δ 7.78 (s, 1H), 7.77 (s, 
1H), 7.20 (s, 1H), 7.08 (s, 1H), 4.33 (d, J = 15.2 Hz, 1H), 4.09 (s, 6H), 4.04 (s, 3H), 
4.03 (s, 3H), 3.56 (d, J = 15.2 Hz, 1H), 3.29 (d, J = 10.7 Hz, 1H), 3.05 (dd, J = 16.3, 2.9 
Hz, 1H), 2.87 (dd, J = 16.3, 10.7 Hz, 1H), 2.43 – 2.22 (m, 2H), 2.08 – 1.95 (m, 1H), 
1.94 – 1.72 (m, 3H), 1.63 – 1.34 (m, 2H) ppm; 13C NMR (75 MHz, CDCl3) δ 148.7 
(2C), 148.5 (C), 148.4 (C), 125.3 (C), 125.2 (C), 124.8 (C), 123.9 (C), 123.6 (C), 123.4 
(C), 103.9 (CH), 103.5 (CH), 103.4 (CH), 103.1 (CH), 57.6 (CH), 56.4 (CH2), 56.2 
(CH2), 56.1 (2xCH3), 56.05 (CH3), 56.02 (CH3), 34.8 (CH2), 33.7 (CH2), 26.0 (CH2), 
24.4 (CH2) ppm; HRMS (ESI-TOF) m/z calcd for C25H30NO4 408.2175 [M+H] +, 
found 408.2185. 
(1S,RS)-N-Allyl-N-(tert-butylsulfinyl)-1-allyl-2-[phenanthren-9-yl]-ethylamine (7a). 
To a solution of sulfinamine 625 (319 mg, 0.87 mmol) in dry THF (3 mL) under argon 
atmosphere at 0 °C was added a solution of KHMDS in THF (0.8 M, 1.6 mL, 1.31 
mmol) via syringe. After stirring for 5 min, allylbromide (150 µL, 1.74 mmol) was 
added to the solution and the reaction mixture was allowed to react for 1 h at 0 °C. After 
this time, a solution of KHMDS in THF (0.8 M, 0.8 mL, 0.65 mmol) was added again 
and the reaction mixture was led to react for 1 h more at 0 °C. After complete 
conversion of starting material (TLC in 8:2 hexane/EtOAc), the reaction was quenched 
by adding a saturated aqueous solution of NH4Cl (5 mL) and the aqueous phase was 
extracted with EtOAc (3 x 10 mL). The collected organic layers were washed with brine 
(2 x 5 mL), dried over MgSO4 and concentrated under reduced pressure. The residue 
was purified by flash column chromatography (8:2  hexane/EtOAc), to give the 
expected product as a yellow wax (301 mg, 85%): [α]D20 +37.6 (c 1.03, CHCl3); Rf 
0.35 (8:2 hexane/EtOAc); IR ν 2979, 1449, 1265, 1061, 994, 918, 727 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.86 – 8.69 (m, 1H), 8.65 (d, J = 8.0 Hz, 1H), 8.18 (s, 1H), 7.85 
(dd, J = 7.8, 1.5 Hz, 1H), 7.69 (s, 1H), 7.67 – 7.54 (m, 4H), 5.85 (dddd, J = 9.4, 7.7, 6.2, 
3.9 Hz, 1H), 5.80 – 5.67 (m, 1H), 5.16 (s, 1H), 5.13 (dd, J = 6.7, 1.1 Hz, 1H), 5.02 – 
4.99 (m, 1H), 4.96 (dd, J = 13.2, 1.7 Hz, 1H), 4.03 (ddt, J = 16.5, 4.6, 1.7 Hz, 1H), 3.75 
(br s, 1H), 3.68 (dd, J = 13.8, 5.4 Hz, 1H), 3.41 (dd, J = 13.8, 8.7 Hz, 1H), 3.27 (dd, J = 
16.5, 7.7 Hz, 1H), 2.46 (ddd, J = 15.2, 8.3, 7.0 Hz, 1H), 2.36 – 2.26 (m, 1H), 1.22 (s, 
9H) ppm; 13C NMR (101 MHz, CDCl3) δ 136.1 (CH), 135.8 (CH), 133.4 (C), 131.8 
(C), 131.2 (C), 130.9 (C), 130.0 (C), 128.7 (CH), 128.4 (CH), 126.8 (CH), 126.7 (CH), 
126.4 (2xCH), 124.6 (CH), 123.5 (CH), 122.5 (CH), 117.9 (CH2), 117.5 (CH2), 61.7 
(CH), 58.3 (C), 46.4 (CH2), 38.4 (CH2), 37.9 (CH2), 24.0 (CH3) ppm; HRMS (EI) m/z 
calcd for C22H22NOS [M+ – C4H9] 349.1417, found 349.1421. 
(1R,SS)-N-Allyl-N-(tert-butylsulfinyl)-1-allyl-2-[phenanthren-9-yl]-ethylamine (ent-
7a).  It was prepared in good yield (197 mg, 85%) from ent–6 (210 mg, 0.57 mmol), 
using the same procedure described for the preparation of 7a, and obtaining identical 
physical data, except for the optical rotation: [α]D20 –37.5 (c 1.03, CHCl3). 
(1S,RS)-N-Allyl-N-(tert-butylsulfinyl)-1-allyl-2-(2,3,6,7-tetramethoxyphenanthren-
9-yl)-ethylamine (7b). Compound ent-121 (193 mg, 0.40 mmol) was submitted to the 
same procedure described to prepare compound 7a. The crude mixture was purified by 
flash column chromatography (6:4 hexane/EtOAc) to give the expected product as a 
white foam (153 mg, 73%): [α]D
20 +51.6 (c 0.87, CHCl3); Rf 0.19 (1:1 hexane/EtOAc); 
IR ν 3079, 2932, 1618, 1507, 1473, 1428, 1251, 1148, 1040, 839, 773 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.84 (s, 1H), 7.77 (s, 1H), 7.55 (br s, 2H), 7.20 (s, 1H), 5.87 – 5.70 
(m, 2H), 5.12 – 5.00 (m, 4H), 4.13 (s, 3H), 4.11 (s, 3H), 4.09 (s, 3H), 4.03 (s, 3H), 3.99 
(dd, J = 16.5, 5.0 Hz, 1H), 3.80 (br s, 1H), 3.61 (dd, J = 13.9, 6.0 Hz, 1H), 3.34 (dd, J = 
13.6, 7.9 Hz, 1H), 3.30 – 3.16 (m, 1H), 2.44 (dt, J = 14.6, 7.4 Hz, 1H), 2.40 – 2.29 (m, 
1H), 1.20 (s, 9H) ppm; 13C NMR (101 MHz, CDCl3) δ 149.2 (C), 149.1 (C), 149.0 (C), 
148.9 (C), 136.0 (CH), 135.9 (CH), 130.9 (C), 126.5 (CH), 126.4 (C), 125.6 (C), 125.1 
(C), 123.9 (C), 117.7 (CH2), 117.6 (CH2), 108.3 (CH), 105.5 (CH), 103.6 (CH), 103.0 
(CH), 60.8 (CH), 58.4 (C), 56.5 (CH3), 56.3 (CH3), 56.2 (CH3), 56.1 (CH3), 47.2 
(CH2), 39.0 (CH2), 38.4 (CH2), 24.0 (CH3) ppm; HRMS (EI) m/z calcd for 
C26H30NO5S [M+ – C4H9] 468.1839, found 468.1849. 
(2S,RS)-N-(tert-Butylsulfinyl)-2-(phenanthren-9-ylmethyl)-1,2,3,6-
tetrahydropyridine (8a). Compound 7a (180 mg, 0.46 mmol) was placed into a 25 mL 
round-bottom-flask followed by second-generation Grubbs’ catalyst (20 mg, 0.023 
mmol). The solids were put under argon atmosphere before dry CH2Cl2 (11 mL) was 
added and the reaction mixture was stirred for 1 h at 25 °C, verifying completion of the 
reaction by TLC (8:2 hexane/EtOAc). The reaction mixture was concentrated and 
purified by flash column chromatography (8:2 hexane/EtOAc) to give the expected 
product as a white foam (159 mg, 95%): mp 142.1 – 143.3 °C; [α]D20 +62.3 (c 1.03, 
CHCl3); Rf 0.21 (8:2 hexane/EtOAc); IR ν 2999, 2948, 2835, 1446, 1244, 1064, 900, 
750, 732 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.74 (dd, J = 6.3, 3.3 Hz, 1H), 8.65 (d, J 
= 8.2 Hz, 1H), 8.23 (dd, J = 6.3, 3.3 Hz, 1H), 7.82 (dd, J = 7.7, 1.5 Hz, 1H), 7.70 – 7.64 
(m, 2H), 7.64 – 7.57 (m, 2H), 7.56 (s, 1H), 5.92 – 5.76 (m, 2H), 4.06 – 3.99 (m, 1H), 
3.95 (d, J = 17.5 Hz, 1H), 3.74 (dd, J = 18.0, 3.7 Hz, 1H), 3.53 (dd, J = 13.6, 5.7 Hz, 
1H), 3.37 (dd, J = 13.6, 9.3 Hz, 1H), 2.39 (dd, J = 18.1, 4.7 Hz, 1H), 1.99 (d, J = 16.3 
Hz, 1H), 1.02 (s, 9H) ppm; 13C NMR (101 MHz, CDCl3) δ 133.9 (C), 131.7 (C), 131.3 
(C), 130.9 (C), 130.0 (C), 128.3 (CH), 128.2 (CH), 126.9 (CH), 126.8 (CH), 126.5 
(CH), 126.4 (CH), 125.3 (CH), 124.8 (CH), 123.8 (CH), 123.4 (CH), 122.6 (CH), 58.5 
(C), 55.6 (CH), 38.4 (CH2), 36.3 (CH2), 27.2 (CH2), 23.2 (CH3) ppm; HRMS (EI) m/z 
calcd for C20H18NOS [M+ – C4H9] 320.1104, found 320.1111. 
(2R,SS)-N-(tert-Butylsulfinyl)-2-(phenanthren-9-ylmethyl)-1,2,3,6-
tetrahydropyridine (ent–8a). It was prepared in good yield (111 mg, 92%) from ent–
7a (130 mg, 0.26 mmol), using the same procedure described for the preparation of 8a, 
and obtaining identical physical data, except for the optical rotation: [α]D20 –60.9 (c 
1.03, CHCl3). 
(2S,RS)-N-(tert-Butylsulfinyl)-2-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)-
1,2,3,6-tetrahydropyridine (8b). Compound 7b (153 mg, 0.29 mmol) was submitted to 
the same procedure described to prepare compound 8a. The crude mixture was purified 
by flash column chromatography (1:1 Hexane/EtOAc) to give the expected product as a 
white foam (135 mg, 93%): [α]D20 +87.8 (c 0.87, CHCl3); Rf 0.22 (1:1 hexane/EtOAc); 
97:3 dr according to HPLC analysis [tR (major) 11.55 min, tR (minor) 13.52 min, see SI 
for details]; IR ν 2949, 2832, 1618, 1508, 1473, 1428, 1251, 1148, 1042, 750 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.77 (s, 1H), 7.75 (s, 1H), 7.35 (s, 1H), 7.16 (s, 
1H), 5.86 (d, J = 2.8 Hz, 2H), 4.14 (s, 3H), 4.13 (s, 3H), 4.11 (s, 3H), 4.08 (dd, J = 10.7, 
5.4 Hz, 1H), 4.04 (s, 3H), 3.92 (d, J = 17.8 Hz, 1H), 3.81 (d, J = 17.8 Hz, 1H), 3.47 (dd, 
J = 13.2, 4.7 Hz, 1H), 3.32 (dd, J = 13.2, 10.7 Hz, 1H), 2.28 (dd, J = 18.0, 5.2 Hz, 1H), 
1.98 (d, J = 17.0 Hz, 1H), 1.11 (s, 9H) ppm; 13C NMR (101 MHz, CDCl3) δ 149.1 (C), 
149.1 (C), 149.0 (C), 131.5 (2xC), 126.3 (C), 125.9 (C), 125.9 (CH), 125.1 (C), 125.0 
(CH), 124.2 (CH), 124.0 (C), 108.0 (CH), 105.8 (CH), 103.5 (CH), 103.0 (CH), 58.6 
(C), 56.5 (CH3), 56.3 (CH3), 56.2 (CH3), 56.0 (CH3), 53.0 (CH), 41.1 (CH2), 35.8 
(CH2), 27.0 (CH2), 23.1 (CH3) ppm; HRMS (EI) m/z calcd for C24H26NO5S [M+ – 
C4H9] 440.1526, found 440.1520. 
(2S,RS)-N-(tert-Butylsulfinyl)-2-(phenanthren-9-ylmethyl)piperidine (9a). A 25 mL 
Schlenk tube was charged with compound 8a (149 mg, 0.40 mmol) and Adams’ catalyst 
(16 mg, 0.04 mmol). Air was evacuated and replaced by an argon atmosphere before 
adding dry CH2Cl2 (7.5 mL) and EtOAc (3 mL). The schlenk tube was connected to a 
hydrogen balloon through a three-ways valve and the reaction mixture was put under 
hydrogen atmosphere after 3 cycles of freeze-pump and thaw. The resulting suspension 
was stirred at 25 °C for 24 h, verifying completion of the reaction by TLC. The reaction 
mixture was concentrated and purified by column chromatography (8:2 hexane/EtOAc) 
to give the expected product as a white foam (139 mg, 93%): mp 163.5 – 164.4 °C; 
[α]D
20 +46.6 (c 0.90 , CHCl3); Rf 0.25  (8:2 hexane/EtOAc); IR ν 2972, 2930, 1452, 
1217, 1077, 1059, 910, 750, 734 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 9.6 
Hz, 1H), 8.65 (d, J = 8.9 Hz, 1H), 8.33 (dd, J = 6.4, 3.0 Hz, 1H), 7.85 – 7.79 (m, 1H), 
7.74 – 7.65 (m, 2H), 7.65 – 7.53 (m, 3H), 3.89 (td, J = 8.4, 3.8 Hz, 1H), 3.77 (dd, J = 
13.3, 4.9 Hz, 1H), 3.50 – 3.37 (m, 1H), 3.31 (dd, J = 13.4, 10.2 Hz, 1H), 3.27 – 3.15 (m, 
1H), 1.96 – 1.76 (m, 1H), 1.74 – 1.44 (m, 6H), 1.13 (s, 9H) ppm; 13C NMR (101 MHz, 
CDCl3) δ 133.7 (C), 131.6 (C), 131.2 (C), 130.8 (C), 129.9 (C), 128.1 (CH), 128.0 
(CH), 126.9 (CH), 126.6 (CH), 126.3 (CH), 126.2 (CH), 125.1 (CH), 123.2 (CH), 122.5 
(CH), 58.3 (C), 57.1 (CH), 42.5 (CH2), 35.8 (CH2), 28.4 (CH2), 26.2 (CH2), 23.3 
(CH3), 19.9 (CH2) ppm; HRMS (EI) m/z calcd for C24H29NOS [M+ – C4H8] 379.1970, 
found 379.1962. 
(2R,SS)-N-(tert-Butylsulfinyl)-2-(phenanthren-9-ylmethyl)piperidine (ent-9a). It 
was prepared in good yield (94 mg, 94%) from ent–8a (101 mg, 0.26 mmol), using the 
same procedure described for the preparation of 9a, and obtaining identical physical 
data except for the optical rotation: [α]D
20 –48.8 (c 0.89, CHCl3). 
(2S,RS)-N-(-tert-Butylsulfinyl)-2-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methyl)piperidine (9b). Compound 8b (119 mg, 0.24 mmol) was submitted to the 
same procedure described to prepare compound 9a. The crude mixture was purified by 
column chromatography (1:1 Hexane/EtOAc) to give the expected product as a white 
foam (100 mg, 84%): [α]D
20 +68.2 (c 0.67, CHCl3); Rf 0.36  (1:1 hexane/EtOAc); 
>99:1 dr according to HPLC analysis [tR (major) 10.61 min, see SI for details]; IR ν 
3082, 2933, 2845, 1618, 1507, 1471, 1428, 1251, 1148, 1039, 912, 751 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.88 (s, 1H), 7.83 (s, 1H), 7.77 (s, 1H), 7.37 (s, 1H), 7.15 (s, 1H), 
4.18 (s, 3H), 4.12 (s, 3H), 4.11 (s, 3H), 4.03 (s, 3H), 3.95 (dd, J = 10.9, 4.2 Hz, 1H), 
3.65 (dd, J = 13.2, 4.0 Hz, 1H), 3.57 – 3.48 (m, 1H), 3.33 (dd, J = 13.2, 11.3 Hz, 1H), 
3.16 (dt, J = 13.0, 3.9 Hz, 1H), 1.99 – 1.84 (m, 1H), 1.77 – 1.58 (m, 3H), 1.56 – 1.50 
(m, 2H), 1.16 (s, 9H) ppm; 13C NMR (101 MHz, CDCl3) δ 149.3 (C), 149.2 (C), 149.2 
(C), 149.1 (C), 131.7 (C), 126.4 (C), 126.0 (C), 125.8 (CH), 125.8 (C) 125.1 (C), 124.1 
(C), 108.1 (CH), 106.3 (CH), 103.5 (CH), 103.1 (CH), 58.7 (C), 56.8 (CH3), 56.4 
(CH3), 56.3 (CH3), 56.1 (CH3), 54.6 (CH), 44.2 (CH2), 35.6 (CH2), 27.8 (CH2), 26.4 
(CH2), 23.4 (CH3), 20.1 (CH2) ppm; HRMS (EI) m/z calcd for C24H28NO5S [M+ – 
C4H9] 442.1683, found 442.1681. 
(S)-11,12,13,14,14a,15-Hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline ((S)-
10). To a pressure tube were sequentially added compound 9a (94 mg, 0.25 mmol), 
trifluoroacetic acid (2 mL, 62 mmol) and 37% formalin (0.95 mL). The reaction mixture 
was put under argon atmosphere and heated to 90 ºC while stirring for 12 h in the dark. 
After cooled to room temperature, the mixture was concentrated under vacuum and the 
residue was diluted with water (5mL) and 4 M solution of NaOH (2 mL). The aqueous 
phase was extracted with EtOAc (3 x 10 mL) and washed with brine (5 mL), dried over 
Na2SO4, and concentrated to dryness. Purification by flash column chromatography 
(72:25:2:1, hexane/CH2Cl2/EtOH/TEA) afforded the desired product as a pale yellow 
solid (65 mg, 91%): [α]D20 +76 (c 0.4, MeOH); Rf 0.17 (72:25:2:1, 
hexane/CH2Cl2/EtOH/TEA); 96:4 er according to chiral HPLC analysis [tR (major) 9.44 
min, tR (minor) 15.79 min, see SI for details]; IR ν 3073, 2926, 2859, 2778, 2750, 1605, 
1440, 1112, 752, 720 cm-1; 1H NMR (300 MHz, CDCl3) δ 8.74 – 8.64 (m, 2H), 8.05 – 
7.95 (m, 1H), 7.94 – 7.84 (m, 1H), 7.67 – 7.55 (m, 4H), 4.49 (d, J = 15.8 Hz, 1H), 3.68 
(d, J = 15.8 Hz, 1H), 3.35 – 3.17 (m, 2H), 3.06 – 2.91 (m, 1H), 2.48 – 2.26 (m, 2H), 
2.12 – 1.99 (m, 1H), 1.95 – 1.70 (m, 3H), 1.63 – 1.35 (m, 2H) ppm; 13C NMR (75 MHz, 
CDCl3) δ 131.1 (C), 129.8 (C), 129.6 (C), 129.4 (C), 127.8 (C), 127.5 (C), 126.8 
(2xCH), 125.9 (CH), 125.8(CH), 123.4 (CH), 123.1 (CH), 122.9 (CH), 122.6 (CH), 57.6 
(CH), 56.4 (CH2), 56.3 (CH2), 34.9 (CH2), 33.9 (CH2), 26.1 (CH2), 24.5 (CH2) ppm; 
HRMS (EI) m/z calcd for C21H21N 287.1674 found 287.1668. 
(R)-11,12,13,14,14a,15-Hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline ((R)-
10). It was prepared in good yield (65 mg, 91%) from ent-9b (80 mg, 0.16 mmol), 
following the same procedure described for the preparation of 10, and obtaining 
identical physical data, except for: [α]D20 –78 (c 0.5, MeOH); 95:5 er according to chiral 
HPLC analysis [tR (minor) 9.41 min, tR (major) 15.75 min, see SI for details]. 
(S)-7-Methoxycryptopleurine ((S)-5). To a pressure tube that contained a solution of 
compound 9b (80 mg, 0.16 mmol) in MeOH (2 mL) at 0ºC was added a solution of HCl 
in dioxane (4M, 0.20 mL). The mixture was put under argon atmosphere and stirred at 
room temperature during 5 h. At this point the mixture was concentrated to dryness, and 
EtOH (4 mL), aqueous formaldehyde (37%, 0.80 mL) and concentrated HCl (12 M, 
0.12 mL), were sequentially added. The reaction mixture was put under argon 
atmosphere , protected from light irradiation and stirred at 90 ºC during 48 h. After 
cooled to room temperature, the mixture was concentrated and distributed between 2 M 
solution of NaOH (10 mL) and CH2Cl2 (15 mL). The aqueous phase was extracted with 
CH2Cl2 (3 x 10 mL) and the collected organic layers were washed with brine (1 x 5 
mL), dried over Na2SO4, and concentrated in vacuum. Purification by flash 
chromatography (72:25:2:1, hexane/CH2Cl2/EtOH/TEA) afforded the desired product 
as a yellow solid (53 mg, 81%). Compound (S)-5 had identical physical data as reported 
for compound (R)- 5, except for: [α]D20 +84 (c 0.9, MeOH) {lit.17 [α]D20 +62.0 (c 0.5, 
CHCl3)}; >99:1 er according to chiral HPLC analysis [tR 14.96 min, see SI for details]. 
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